pharmacometrics phase 2 proof-of-concept dose selection phase 3/marketing
Published 3 years ago • 140 plays • Length 27:42Download video MP4
Download video MP3
Similar videos
-
28:51
pharmacometrics in phase 1: first in human and dose selection for phase 2
-
20:56
pharmacometrics in phase 3 – data integration and analysis to support dose and labeling for the nda
-
25:18
pharmacometrics post approval fulfillment of requirements label extension and life-cycle management
-
46:57
case studies of phase 2 adaptive dose-finding trials - jim bolognese
-
1:05:36
project optimus – fda’s new dose optimization & selection paradigm in oncology drug development
-
4:56
introduction to phase ii track with joel owen
-
30:42
impact of midd during phase ii new drug development a regulatory perspective
-
6:55
dmf section 3.2.s.7 - stability
-
47:08
lecture 3 - fda drug approval 101- reading and interpreting cancer trials series
-
3:18
nursing school : clinical simulations 🩺
-
4:12
adaptive 2-stage design supporting the fulyzaq® approval
-
27:02
optimizing sample size of a phase iii trial with simulx using a phase ii poppd model
-
58:45
best practices in clinical pharmacology gap analysis
-
42:17
optimizing drug development with model-informed decision making
-
8:35
the phase 3 valor trial: adaptive sample size re-estimation
-
7:43
introduction to fih/phase 1 track